ResistancePlus® MG FleXible offers simultaneous detection and identification of Mycoplasma genitalium and azithromycin (macrolide) resistance in ~ 2 hours to support appropriate treatment decisions at the earliest opportunity for improved patient management.
**ResistancePlus® MG FleXible**

*ResistancePlus® MG FleXible* brings **accuracy and simplicity** to your lab in combination with GeneXpert® Systems* for a complete solution. Detect both *M. genitalium* and macrolide resistance markers in a single test and help overcome the challenges of treating *M. genitalium* due to high levels of azithromycin resistance.4

**The Challenges:**

- *M. genitalium* is a recognised Sexually Transmitted Infection (STI), treated syndromically, with clinical presentation similar to that of *Chlamydia trachomatis*.1
- Prevalence of *M. genitalium* infections in the general population ranges from 1-3%, with an increased incidence in men with non-gonococcal urethritis (NGU) (10-20%).2
- *M. genitalium* infections contribute to 10–35% of non-chlamydial non-gonococcal urethritis in men and in women, it is also associated with cervicitis and pelvic inflammatory disease (PID).3
- *M. genitalium* treatment is challenging due to high levels of macrolide resistance.4

**The Need:**

- Macrolide resistance testing is **recommended by international and local guidelines** on management of *M. genitalium* infections.2,3,5-7
- Macrolide resistance testing can guide appropriate treatment choice enabling Resistance Guided Therapy.5
- Resistance Guided Therapy is clinically demonstrated to **improve patient cure rate** and overall patient management.8
- Fast detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.8

**The Solution:**

- *ResistancePlus® MG FleXible* detects both *M. genitalium* and macrolide resistance in ~ 2 hours.
- *ResistancePlus® MG FleXible* offers a fast and simple solution in combination with GeneXpert® Systems. Easily implemented into your existing workflow or setting, with minimal preparation time ~ 10 mins.
- High performance test validated on **wide range of specimen types** and collection devices, including urine and swabs (vaginal, cervical, rectal).**

* CE-IVD. In Vitro Diagnostic Medical Device.
** Validated specimens: male and female urine, vaginal swab, cervical swab, rectal swab, urethral swab, from symptomatic and asymptomatic patients. Validated collection kits: Xpert® Vaginal/Endocervical and Xpert® Urine Specimen Collection Kits. Neat urine, Regular FLOQSwab™ in 3 ml of UTM™ media, cobas PCR collection media. For details refer to the *ResistancePlus® MG FleXible Instructions For Use (IF-IV0012)*
Impact on Patient Pathway

Improving patient management

**ResistancePlus® MG FleXible** provides therapeutic guidance recommendations, enabling clinicians to make informed treatment decisions. Resistance guided therapy is clinically demonstrated to increase overall patient cure rate.\(^8\)

Patient receives the appropriate antibiotic treatment—improving cure rate and time to cure

Risk of ineffective treatment—increased time to cure and potential spread of resistant infection

**ResistancePlus® MG FleXible**

Validated on a wide range of sample types including **rectal**, male and female **urine**, and common collection **swab** kits including Xpert\(^\circledR\) CT/NG Vaginal/Endocervical Specimen Collection kit and Xpert\(^\circledR\) CT/NG Urine Specimen Collection Kit.\(^7\)

**Clinical Performance†**

<table>
<thead>
<tr>
<th></th>
<th>MG Detection</th>
<th>Resistance Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitivity</strong></td>
<td>100%</td>
<td>92.9%</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>96.3%</td>
<td>100%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expected MG</th>
<th>33/33</th>
<th>1/1</th>
<th>3/4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male urine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected MG</td>
<td>22/22</td>
<td>6/6</td>
<td>10/10</td>
</tr>
<tr>
<td><strong>Female vaginal swab</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^†\) All performance results at 95% confidence interval. For details refer to the **ResistancePlus® MG FleXible** Instructions For Use (IF-IV0012)
Simple Implementation into Existing Workflow
Easy preparation — Hands-on time < 10 min

1. Prepare reaction mix
2. Transfer samples and Internal Control
3. Insert Cartridge and start test, results in ~2 hours

Product | Size | Cat#
--- | --- | ---
ResistancePlus® MG FleXible | 10 tests | S2A-2000410
ResistancePlus® MG S2A Positive Control | 10 tests | S2A-95004

**ResistancePlus® MG FleXible**
Improve patient management. Test for macrolide resistance.

References:


ResistancePlus® MG FleXible tests are developed and manufactured by SpeeDx Pty Ltd, Sydney. PlexPCR® & ResistancePlus® are trademarks of SpeeDx Pty Ltd. Other copyright and trademarks are the property of the respective owners. SpeeDx Pty Ltd products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.

Europe - SpeeDx Ltd.
+44 (0)333 577 5210
sales.uk@speedx.com.au
Acre House 11/15 William Road
London NW1 3ER United Kingdom

Cepheid European Headquarters
+33-563-82-53-00
cepheid@cepheidfrance.fr
Vira Soleilh
81470 Maurens-Scopont France

Exclusively distributed by Cepheid under the FleXible® for GeneXpert® System program.